$ARRY Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in ARRAY BIOPHARMA INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in ARRAY BIOPHARMA INC. Get notifications about new insider transactions in ARRAY BIOPHARMA INC for free.
Page: < prev 1 2 3 4 5 6 7 7 next >
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 04 2017 | ARRY | ARRAY BIOPHARMA IN ... | LEFKOFF KYLE | Gift | G | 0.00 | 2,000 | 0 | 6,585 | 8.6 K to 6.6 K (-23.30 %) | |
| Mar 30 2017 | ARRY | ARRAY BIOPHARMA IN ... | BAUM CHARLES M | Option Exercise | M | 3.87 | 25,000 | 96,750 | 0 | ||
| Mar 30 2017 | ARRY | ARRAY BIOPHARMA IN ... | BAUM CHARLES M | Sell | S | 9.27 | 25,000 | 231,750 | 5,000 | 30 K to 5 K (-83.33 %) | |
| Mar 30 2017 | ARRY | ARRAY BIOPHARMA IN ... | BAUM CHARLES M | Buy | M | 3.87 | 25,000 | 96,750 | 30,000 | 5 K to 30 K (+500.00 %) | |
| Dec 29 2016 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Option Exercise | A | 8.79 | 562,500 | 4,944,375 | 562,500 | |
| Dec 29 2016 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Option Exercise | A | 0.00 | 93,750 | 0 | 93,750 | |
| Dec 29 2016 | ARRY | ARRAY BIOPHARMA IN ... | Sandor Victor | Chief Medical Offic ... | Option Exercise | A | 8.79 | 270,828 | 2,380,578 | 270,828 | |
| Dec 29 2016 | ARRY | ARRAY BIOPHARMA IN ... | Sandor Victor | Chief Medical Offic ... | Option Exercise | A | 0.00 | 45,138 | 0 | 45,138 | |
| Dec 29 2016 | ARRY | ARRAY BIOPHARMA IN ... | Saccomano Nicholas A | CSO | Option Exercise | A | 8.79 | 131,250 | 1,153,688 | 131,250 | |
| Dec 29 2016 | ARRY | ARRAY BIOPHARMA IN ... | Saccomano Nicholas A | CSO | Option Exercise | A | 0.00 | 21,875 | 0 | 21,875 | |
| Dec 29 2016 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrew R | COO | Option Exercise | A | 8.79 | 313,989 | 2,759,963 | 313,989 | |
| Dec 29 2016 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrew R | COO | Option Exercise | A | 0.00 | 52,331 | 0 | 52,331 | |
| Dec 29 2016 | ARRY | ARRAY BIOPHARMA IN ... | MOORE JOHN R | VP, General Counsel | Option Exercise | A | 8.79 | 131,250 | 1,153,688 | 131,250 | |
| Dec 29 2016 | ARRY | ARRAY BIOPHARMA IN ... | MOORE JOHN R | VP, General Counsel | Option Exercise | A | 0.00 | 21,875 | 0 | 21,875 | |
| Dec 29 2016 | ARRY | ARRAY BIOPHARMA IN ... | Haddock Jason | CFO | Option Exercise | A | 8.79 | 105,302 | 925,605 | 105,302 | |
| Dec 29 2016 | ARRY | ARRAY BIOPHARMA IN ... | Haddock Jason | CFO | Option Exercise | A | 0.00 | 17,550 | 0 | 17,550 | |
| Oct 31 2016 | ARRY | ARRAY BIOPHARMA IN ... | VAN LUNSEN GIL J | Option Exercise | M | 0.00 | 5,000 | 0 | 0 | ||
| Oct 31 2016 | ARRY | ARRAY BIOPHARMA IN ... | VAN LUNSEN GIL J | Option Exercise | A | 5.95 | 25,000 | 148,750 | 25,000 | ||
| Oct 31 2016 | ARRY | ARRAY BIOPHARMA IN ... | VAN LUNSEN GIL J | Option Exercise | A | 0.00 | 5,000 | 0 | 5,000 | ||
| Oct 31 2016 | ARRY | ARRAY BIOPHARMA IN ... | VAN LUNSEN GIL J | Buy | M | 5.83 | 5,000 | 29,150 | 10,260 | 5.3 K to 10.3 K (+95.06 %) | |
| Oct 31 2016 | ARRY | ARRAY BIOPHARMA IN ... | Orwin John A | Option Exercise | M | 0.00 | 5,000 | 0 | 0 | ||
| Oct 31 2016 | ARRY | ARRAY BIOPHARMA IN ... | Orwin John A | Option Exercise | A | 5.95 | 25,000 | 148,750 | 25,000 | ||
| Oct 31 2016 | ARRY | ARRAY BIOPHARMA IN ... | Orwin John A | Option Exercise | A | 0.00 | 5,000 | 0 | 5,000 | ||
| Oct 31 2016 | ARRY | ARRAY BIOPHARMA IN ... | Orwin John A | Buy | M | 5.83 | 5,000 | 29,150 | 5,000 | 0 to 5 K | |
| Oct 31 2016 | ARRY | ARRAY BIOPHARMA IN ... | LEFKOFF KYLE | Option Exercise | M | 0.00 | 5,000 | 0 | 0 | ||
| Oct 31 2016 | ARRY | ARRAY BIOPHARMA IN ... | LEFKOFF KYLE | Option Exercise | A | 5.95 | 25,000 | 148,750 | 25,000 | ||
| Oct 31 2016 | ARRY | ARRAY BIOPHARMA IN ... | LEFKOFF KYLE | Option Exercise | A | 0.00 | 5,000 | 0 | 5,000 | ||
| Oct 31 2016 | ARRY | ARRAY BIOPHARMA IN ... | LEFKOFF KYLE | Buy | M | 5.83 | 5,000 | 29,150 | 8,585 | 3.6 K to 8.6 K (+139.47 %) | |
| Oct 31 2016 | ARRY | ARRAY BIOPHARMA IN ... | Fyfe Gwen A. | Option Exercise | M | 0.00 | 5,000 | 0 | 0 | ||
| Oct 31 2016 | ARRY | ARRAY BIOPHARMA IN ... | Fyfe Gwen A. | Option Exercise | A | 5.95 | 25,000 | 148,750 | 25,000 | ||
| Oct 31 2016 | ARRY | ARRAY BIOPHARMA IN ... | Fyfe Gwen A. | Option Exercise | A | 0.00 | 5,000 | 0 | 5,000 | ||
| Oct 31 2016 | ARRY | ARRAY BIOPHARMA IN ... | Fyfe Gwen A. | Buy | M | 5.83 | 5,000 | 29,150 | 5,000 | 0 to 5 K | |
| Oct 31 2016 | ARRY | ARRAY BIOPHARMA IN ... | BAUM CHARLES M | Option Exercise | M | 0.00 | 5,000 | 0 | 0 | ||
| Oct 31 2016 | ARRY | ARRAY BIOPHARMA IN ... | BAUM CHARLES M | Option Exercise | A | 5.95 | 25,000 | 148,750 | 25,000 | ||
| Oct 31 2016 | ARRY | ARRAY BIOPHARMA IN ... | BAUM CHARLES M | Option Exercise | A | 0.00 | 5,000 | 0 | 5,000 | ||
| Oct 31 2016 | ARRY | ARRAY BIOPHARMA IN ... | BAUM CHARLES M | Buy | M | 5.83 | 5,000 | 29,150 | 5,000 | 0 to 5 K | |
| Sep 30 2016 | ARRY | ARRAY BIOPHARMA IN ... | Redmile Group, LLC | 10% Owner | Sell | S | 6.36 | 2,492,578 | 15,852,796 | 16,658,072 | 19.2 M to 16.7 M (-13.02 %) |
| Sep 23 2016 | ARRY | ARRAY BIOPHARMA IN ... | Sandor Victor | Chief Medical Offic ... | Option Exercise | M | 0.00 | 95,890 | 0 | 0 | |
| Sep 23 2016 | ARRY | ARRAY BIOPHARMA IN ... | Sandor Victor | Chief Medical Offic ... | Payment of Exercise | F | 3.69 | 31,117 | 114,822 | 169,616 | 200.7 K to 169.6 K (-15.50 %) |
| Sep 23 2016 | ARRY | ARRAY BIOPHARMA IN ... | Sandor Victor | Chief Medical Offic ... | Buy | M | 3.69 | 95,890 | 353,834 | 200,733 | 104.8 K to 200.7 K (+91.46 %) |
| Sep 16 2016 | ARRY | ARRAY BIOPHARMA IN ... | Redmile Group, LLC | 10% Owner | Buy | P | 3.50 | 28,000 | 98,000 | 19,150,650 | 19.1 M to 19.2 M (+0.15 %) |
| Sep 16 2016 | ARRY | ARRAY BIOPHARMA IN ... | Redmile Group, LLC | 10% Owner | Sell | S | 3.54 | 7,300 | 25,842 | 19,122,650 | 19.1 M to 19.1 M (-0.04 %) |
| Sep 16 2016 | ARRY | ARRAY BIOPHARMA IN ... | Redmile Group, LLC | 10% Owner | Buy | P | 3.51 | 372,000 | 1,305,720 | 19,129,950 | 18.8 M to 19.1 M (+1.98 %) |
| Sep 16 2016 | ARRY | ARRAY BIOPHARMA IN ... | Redmile Group, LLC | 10% Owner | Sell | S | 3.50 | 392,700 | 1,374,450 | 18,757,950 | 19.2 M to 18.8 M (-2.05 %) |
| Apr 05 2016 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Option Exercise | A | 3.00 | 453,750 | 1,361,250 | 453,750 | |
| Apr 05 2016 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Option Exercise | A | 0.00 | 75,625 | 0 | 75,625 | |
| Apr 05 2016 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Payment of Exercise | F | 3.00 | 5,878 | 17,634 | 107,463 | 113.3 K to 107.5 K (-5.19 %) |
| Apr 05 2016 | ARRY | ARRAY BIOPHARMA IN ... | Sandor Victor | Chief Medical Offic ... | Option Exercise | A | 3.00 | 187,500 | 562,500 | 187,500 | |
| Apr 05 2016 | ARRY | ARRAY BIOPHARMA IN ... | Sandor Victor | Chief Medical Offic ... | Option Exercise | A | 0.00 | 31,250 | 0 | 31,250 | |
| Apr 05 2016 | ARRY | ARRAY BIOPHARMA IN ... | Sandor Victor | Chief Medical Offic ... | Payment of Exercise | F | 3.00 | 2,651 | 7,953 | 104,843 | 107.5 K to 104.8 K (-2.47 %) |
| Apr 05 2016 | ARRY | ARRAY BIOPHARMA IN ... | Saccomano Nicholas A | CSO | Option Exercise | A | 3.00 | 165,000 | 495,000 | 165,000 | |
| Apr 05 2016 | ARRY | ARRAY BIOPHARMA IN ... | Saccomano Nicholas A | CSO | Option Exercise | A | 0.00 | 27,500 | 0 | 27,500 | |
| Apr 05 2016 | ARRY | ARRAY BIOPHARMA IN ... | Saccomano Nicholas A | CSO | Payment of Exercise | F | 3.00 | 2,564 | 7,692 | 35,186 | 37.8 K to 35.2 K (-6.79 %) |
| Apr 05 2016 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrews R | COO | Option Exercise | A | 3.00 | 236,250 | 708,750 | 236,250 | |
| Apr 05 2016 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrews R | COO | Option Exercise | A | 0.00 | 39,375 | 0 | 39,375 | |
| Apr 05 2016 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrews R | COO | Payment of Exercise | F | 3.00 | 3,367 | 10,101 | 36,008 | 39.4 K to 36 K (-8.55 %) |
| Apr 05 2016 | ARRY | ARRAY BIOPHARMA IN ... | MOORE JOHN R | VP, General Counsel | Option Exercise | A | 3.00 | 161,250 | 483,750 | 161,250 | |
| Apr 05 2016 | ARRY | ARRAY BIOPHARMA IN ... | MOORE JOHN R | VP, General Counsel | Option Exercise | A | 0.00 | 26,875 | 0 | 26,875 | |
| Apr 05 2016 | ARRY | ARRAY BIOPHARMA IN ... | MOORE JOHN R | VP, General Counsel | Payment of Exercise | F | 3.00 | 2,505 | 7,515 | 39,754 | 42.3 K to 39.8 K (-5.93 %) |
| Jan 22 2016 | ARRY | ARRAY BIOPHARMA IN ... | Redmile Group, LLC | 10% Owner | Buy | P | 3.19 | 300,000 | 957,000 | 19,150,650 | 18.9 M to 19.2 M (+1.59 %) |
| Jan 14 2016 | ARRY | ARRAY BIOPHARMA IN ... | Redmile Group, LLC | 10% Owner | Buy | P | 3.60 | 75,000 | 270,000 | 18,850,650 | 18.8 M to 18.9 M (+0.40 %) |
| Jan 11 2016 | ARRY | ARRAY BIOPHARMA IN ... | Redmile Group, LLC | 10% Owner | Buy | P | 3.54 | 275,000 | 973,500 | 18,775,650 | 18.5 M to 18.8 M (+1.49 %) |
| Jan 11 2016 | ARRY | ARRAY BIOPHARMA IN ... | Redmile Group, LLC | 10% Owner | Buy | P | 3.72 | 350,000 | 1,302,000 | 18,500,650 | 18.2 M to 18.5 M (+1.93 %) |
| Jan 11 2016 | ARRY | ARRAY BIOPHARMA IN ... | Redmile Group, LLC | 10% Owner | Buy | P | 3.73 | 300,000 | 1,119,000 | 18,150,650 | 17.9 M to 18.2 M (+1.68 %) |
| Nov 02 2015 | ARRY | ARRAY BIOPHARMA IN ... | VAN LUNSEN GIL J | Option Exercise | A | 5.13 | 25,000 | 128,250 | 25,000 | ||
| Nov 02 2015 | ARRY | ARRAY BIOPHARMA IN ... | VAN LUNSEN GIL J | Option Exercise | A | 0.00 | 5,000 | 0 | 5,000 | ||
| Nov 02 2015 | ARRY | ARRAY BIOPHARMA IN ... | Orwin John A | Option Exercise | A | 5.13 | 25,000 | 128,250 | 25,000 | ||
| Nov 02 2015 | ARRY | ARRAY BIOPHARMA IN ... | Orwin John A | Option Exercise | A | 0.00 | 5,000 | 0 | 5,000 | ||
| Nov 02 2015 | ARRY | ARRAY BIOPHARMA IN ... | LEFKOFF KYLE | Option Exercise | A | 5.13 | 25,000 | 128,250 | 25,000 | ||
| Nov 02 2015 | ARRY | ARRAY BIOPHARMA IN ... | LEFKOFF KYLE | Option Exercise | A | 0.00 | 5,000 | 0 | 5,000 | ||
| Nov 02 2015 | ARRY | ARRAY BIOPHARMA IN ... | Fyfe Gwen A. | Option Exercise | A | 5.13 | 25,000 | 128,250 | 25,000 | ||
| Nov 02 2015 | ARRY | ARRAY BIOPHARMA IN ... | Fyfe Gwen A. | Option Exercise | A | 0.00 | 5,000 | 0 | 5,000 | ||
| Nov 02 2015 | ARRY | ARRAY BIOPHARMA IN ... | BAUM CHARLES M | Option Exercise | A | 5.13 | 25,000 | 128,250 | 25,000 | ||
| Nov 02 2015 | ARRY | ARRAY BIOPHARMA IN ... | BAUM CHARLES M | Option Exercise | A | 0.00 | 5,000 | 0 | 5,000 | ||
| Oct 01 2015 | ARRY | ARRAY BIOPHARMA IN ... | Redmile Group, LLC | 10% Owner | Buy | P | 4.50 | 100,140 | 450,630 | 18,033,102 | 17.9 M to 18 M (+0.56 %) |
| Oct 01 2015 | ARRY | ARRAY BIOPHARMA IN ... | Redmile Group, LLC | 10% Owner | Buy | P | 4.67 | 182,452 | 852,051 | 17,932,962 | 17.8 M to 17.9 M (+1.03 %) |
| Oct 01 2015 | ARRY | ARRAY BIOPHARMA IN ... | Redmile Group, LLC | 10% Owner | Buy | P | 4.56 | 500,000 | 2,280,000 | 17,750,510 | 17.3 M to 17.8 M (+2.90 %) |
| Sep 24 2015 | ARRY | ARRAY BIOPHARMA IN ... | Sandor Victor | Chief Medical Offic ... | Option Exercise | M | 0.00 | 95,891 | 0 | 95,891 | |
| Sep 24 2015 | ARRY | ARRAY BIOPHARMA IN ... | Sandor Victor | Chief Medical Offic ... | Payment of Exercise | F | 5.18 | 31,165 | 161,435 | 107,494 | 138.7 K to 107.5 K (-22.48 %) |
| Sep 24 2015 | ARRY | ARRAY BIOPHARMA IN ... | Sandor Victor | Chief Medical Offic ... | Buy | M | 5.18 | 95,891 | 496,715 | 138,659 | 42.8 K to 138.7 K (+224.21 %) |
| Aug 28 2015 | ARRY | ARRAY BIOPHARMA IN ... | Redmile Group, LLC | 10% Owner | Buy | P | 5.48 | 49,900 | 273,452 | 17,250,510 | 17.2 M to 17.3 M (+0.29 %) |
| Aug 25 2015 | ARRY | ARRAY BIOPHARMA IN ... | Redmile Group, LLC | 10% Owner | Buy | P | 5.45 | 220,000 | 1,199,000 | 17,200,610 | 17 M to 17.2 M (+1.30 %) |
| Aug 25 2015 | ARRY | ARRAY BIOPHARMA IN ... | Redmile Group, LLC | 10% Owner | Buy | P | 5.32 | 410,000 | 2,181,200 | 16,980,610 | 16.6 M to 17 M (+2.47 %) |
| Aug 25 2015 | ARRY | ARRAY BIOPHARMA IN ... | Redmile Group, LLC | 10% Owner | Buy | P | 5.45 | 160,000 | 872,000 | 16,570,610 | 16.4 M to 16.6 M (+0.97 %) |
| Aug 13 2015 | ARRY | ARRAY BIOPHARMA IN ... | Redmile Group, LLC | 10% Owner | Buy | P | 5.93 | 205,000 | 1,215,650 | 16,410,610 | 16.2 M to 16.4 M (+1.26 %) |
| Aug 13 2015 | ARRY | ARRAY BIOPHARMA IN ... | Redmile Group, LLC | 10% Owner | Buy | P | 5.85 | 327,500 | 1,915,875 | 16,205,610 | 15.9 M to 16.2 M (+2.06 %) |
| Aug 10 2015 | ARRY | ARRAY BIOPHARMA IN ... | Redmile Group, LLC | 10% Owner | Buy | P | 5.81 | 180,000 | 1,045,800 | 15,878,110 | 15.7 M to 15.9 M (+1.15 %) |
| Aug 10 2015 | ARRY | ARRAY BIOPHARMA IN ... | Redmile Group, LLC | 10% Owner | Buy | P | 5.67 | 276,543 | 1,567,999 | 15,698,110 | 15.4 M to 15.7 M (+1.79 %) |
| Aug 10 2015 | ARRY | ARRAY BIOPHARMA IN ... | Redmile Group, LLC | 10% Owner | Buy | P | 5.85 | 592,450 | 3,465,833 | 15,421,567 | 14.8 M to 15.4 M (+4.00 %) |
| May 12 2015 | ARRY | ARRAY BIOPHARMA IN ... | BAUM CHARLES M | Director | Option Exercise | M | 3.86 | 25,000 | 96,500 | 0 | |
| May 12 2015 | ARRY | ARRAY BIOPHARMA IN ... | BAUM CHARLES M | Director | Sell | S | 7.38 | 25,000 | 184,483 | 0 | 25 K to 0 (-100.00 %) |
| May 12 2015 | ARRY | ARRAY BIOPHARMA IN ... | BAUM CHARLES M | Director | Buy | M | 3.86 | 25,000 | 96,500 | 25,000 | 0 to 25 K |
| Apr 03 2015 | ARRY | ARRAY BIOPHARMA IN ... | Saccomano Nicholas A | CSO | Option Exercise | A | 7.30 | 165,000 | 1,204,500 | 165,000 | |
| Apr 03 2015 | ARRY | ARRAY BIOPHARMA IN ... | Saccomano Nicholas A | CSO | Grant | A | 0.00 | 27,500 | 0 | 35,800 | 8.3 K to 35.8 K (+331.33 %) |
| Apr 03 2015 | ARRY | ARRAY BIOPHARMA IN ... | MOORE JOHN R | VP, General Counsel | Option Exercise | A | 7.30 | 161,250 | 1,177,125 | 161,250 | |
| Apr 03 2015 | ARRY | ARRAY BIOPHARMA IN ... | MOORE JOHN R | VP, General Counsel | Grant | A | 0.00 | 26,875 | 0 | 42,259 | 15.4 K to 42.3 K (+174.69 %) |
| Apr 03 2015 | ARRY | ARRAY BIOPHARMA IN ... | Sandor Victor | Chief Medical Offic ... | Option Exercise | A | 7.30 | 187,500 | 1,368,750 | 187,500 | |
| Apr 03 2015 | ARRY | ARRAY BIOPHARMA IN ... | Sandor Victor | Chief Medical Offic ... | Grant | A | 0.00 | 31,250 | 0 | 42,768 | 11.5 K to 42.8 K (+271.31 %) |
| Apr 03 2015 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrews R | SVP, Commercial Ope ... | Option Exercise | A | 7.30 | 236,250 | 1,724,625 | 236,250 | |
| Apr 03 2015 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrews R | SVP, Commercial Ope ... | Option Exercise | A | 8.20 | 50,000 | 410,000 | 50,000 | |
| Apr 03 2015 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrews R | SVP, Commercial Ope ... | Grant | A | 0.00 | 39,375 | 0 | 39,375 | 0 to 39.4 K |
| Apr 03 2015 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Option Exercise | A | 7.30 | 453,750 | 3,312,375 | 453,750 | |
| Apr 03 2015 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Grant | A | 0.00 | 75,625 | 0 | 108,166 | 32.5 K to 108.2 K (+232.40 %) |
| Mar 04 2015 | ARRY | ARRAY BIOPHARMA IN ... | LEFKOFF KYLE | Director | Option Exercise | M | 2.46 | 20,000 | 49,200 | 0 | |
| Mar 04 2015 | ARRY | ARRAY BIOPHARMA IN ... | LEFKOFF KYLE | Director | Option Exercise | M | 3.51 | 20,000 | 70,200 | 0 | |
| Mar 04 2015 | ARRY | ARRAY BIOPHARMA IN ... | LEFKOFF KYLE | Director | Option Exercise | M | 1.74 | 15,000 | 26,100 | 0 | |
| Mar 04 2015 | ARRY | ARRAY BIOPHARMA IN ... | LEFKOFF KYLE | Director | Option Exercise | M | 3.37 | 15,000 | 50,550 | 0 | |
| Mar 04 2015 | ARRY | ARRAY BIOPHARMA IN ... | LEFKOFF KYLE | Director | Sell | S | 8.00 | 70,000 | 560,070 | 3,585 | 73.6 K to 3.6 K (-95.13 %) |
| Mar 04 2015 | ARRY | ARRAY BIOPHARMA IN ... | LEFKOFF KYLE | Director | Buy | M | 2.46 | 20,000 | 49,200 | 73,585 | 53.6 K to 73.6 K (+37.32 %) |
| Mar 04 2015 | ARRY | ARRAY BIOPHARMA IN ... | LEFKOFF KYLE | Director | Buy | M | 3.51 | 20,000 | 70,200 | 53,585 | 33.6 K to 53.6 K (+59.55 %) |
| Mar 04 2015 | ARRY | ARRAY BIOPHARMA IN ... | LEFKOFF KYLE | Director | Buy | M | 1.74 | 15,000 | 26,100 | 33,585 | 18.6 K to 33.6 K (+80.71 %) |
| Mar 04 2015 | ARRY | ARRAY BIOPHARMA IN ... | LEFKOFF KYLE | Director | Buy | M | 3.37 | 15,000 | 50,550 | 18,585 | 3.6 K to 18.6 K (+418.41 %) |
| Mar 04 2015 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrews R | SVP, Commercial Ope ... | Option Exercise | M | 0.00 | 32,069 | 0 | 32,069 | |
| Mar 04 2015 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrews R | SVP, Commercial Ope ... | Sell | S | 8.25 | 21,576 | 178,002 | 0 | 21.6 K to 0 (-100.00 %) |
| Mar 04 2015 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrews R | SVP, Commercial Ope ... | Payment of Exercise | F | 7.96 | 10,493 | 83,524 | 21,576 | 32.1 K to 21.6 K (-32.72 %) |
| Mar 04 2015 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrews R | SVP, Commercial Ope ... | Buy | M | 7.96 | 32,069 | 255,269 | 32,069 | 0 to 32.1 K |
| Mar 04 2015 | ARRY | ARRAY BIOPHARMA IN ... | Sandor Victor | Chief Medical Offic ... | Option Exercise | M | 0.00 | 17,440 | 0 | 17,440 | |
| Mar 04 2015 | ARRY | ARRAY BIOPHARMA IN ... | Sandor Victor | Chief Medical Offic ... | Payment of Exercise | F | 7.96 | 5,805 | 46,208 | 11,635 | 17.4 K to 11.6 K (-33.29 %) |
| Mar 04 2015 | ARRY | ARRAY BIOPHARMA IN ... | Sandor Victor | Chief Medical Offic ... | Buy | M | 7.96 | 17,440 | 138,822 | 17,440 | 0 to 17.4 K |
| Mar 04 2015 | ARRY | ARRAY BIOPHARMA IN ... | MOORE JOHN R | VP, General Counsel | Option Exercise | M | 0.00 | 22,906 | 0 | 22,906 | |
| Mar 04 2015 | ARRY | ARRAY BIOPHARMA IN ... | MOORE JOHN R | VP, General Counsel | Payment of Exercise | F | 7.96 | 7,542 | 60,034 | 15,364 | 22.9 K to 15.4 K (-32.93 %) |
| Mar 04 2015 | ARRY | ARRAY BIOPHARMA IN ... | MOORE JOHN R | VP, General Counsel | Buy | M | 7.96 | 22,906 | 182,332 | 22,906 | 0 to 22.9 K |
| Mar 04 2015 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Option Exercise | M | 0.00 | 77,881 | 0 | 77,881 | |
| Mar 04 2015 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Sell | S | 8.25 | 40,000 | 330,000 | 12,927 | 52.9 K to 12.9 K (-75.58 %) |
| Mar 04 2015 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Payment of Exercise | F | 7.96 | 24,954 | 198,634 | 52,927 | 77.9 K to 52.9 K (-32.04 %) |
| Mar 04 2015 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Buy | M | 7.96 | 77,881 | 619,933 | 77,881 | 0 to 77.9 K |
| Mar 04 2015 | ARRY | ARRAY BIOPHARMA IN ... | Saccomano Nicholas A | CSO | Option Exercise | M | 0.00 | 11,453 | 0 | 11,453 | |
| Mar 04 2015 | ARRY | ARRAY BIOPHARMA IN ... | Saccomano Nicholas A | CSO | Payment of Exercise | F | 7.96 | 4,033 | 32,103 | 7,420 | 11.5 K to 7.4 K (-35.21 %) |
| Mar 04 2015 | ARRY | ARRAY BIOPHARMA IN ... | Saccomano Nicholas A | CSO | Buy | M | 7.96 | 11,453 | 91,166 | 11,453 | 0 to 11.5 K |
| Mar 04 2015 | ARRY | ARRAY BIOPHARMA IN ... | SNITMAN DAVID | COO and VP, Busines ... | Option Exercise | M | 0.00 | 11,453 | 0 | 11,453 | |
| Mar 04 2015 | ARRY | ARRAY BIOPHARMA IN ... | SNITMAN DAVID | COO and VP, Busines ... | Payment of Exercise | F | 7.96 | 3,976 | 31,649 | 7,477 | 11.5 K to 7.5 K (-34.72 %) |
| Mar 04 2015 | ARRY | ARRAY BIOPHARMA IN ... | SNITMAN DAVID | COO and VP, Busines ... | Buy | M | 7.96 | 11,453 | 91,166 | 11,453 | 0 to 11.5 K |
| Oct 31 2014 | ARRY | ARRAY BIOPHARMA IN ... | VAN LUNSEN GIL J | Director | Option Exercise | A | 3.87 | 25,000 | 96,750 | 25,000 | |
| Oct 31 2014 | ARRY | ARRAY BIOPHARMA IN ... | Orwin John A | Director | Option Exercise | A | 3.87 | 25,000 | 96,750 | 25,000 | |
| Oct 31 2014 | ARRY | ARRAY BIOPHARMA IN ... | LEFKOFF KYLE | Director | Option Exercise | A | 3.87 | 25,000 | 96,750 | 25,000 | |
| Oct 31 2014 | ARRY | ARRAY BIOPHARMA IN ... | Fyfe Gwen A. | Director | Option Exercise | A | 3.87 | 25,000 | 96,750 | 25,000 | |
| Oct 31 2014 | ARRY | ARRAY BIOPHARMA IN ... | BAUM CHARLES M | Director | Option Exercise | A | 3.87 | 25,000 | 96,750 | 25,000 | |
| Aug 20 2014 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrews R | SVP, Commercial Ope ... | Option Exercise | A | 0.00 | 64,137 | 0 | 64,137 | |
| Aug 20 2014 | ARRY | ARRAY BIOPHARMA IN ... | MOORE JOHN R | VP, General Counsel | Option Exercise | A | 0.00 | 45,812 | 0 | 45,812 | |
| Aug 20 2014 | ARRY | ARRAY BIOPHARMA IN ... | Saccomano Nicholas A | CSO | Option Exercise | A | 0.00 | 22,906 | 0 | 22,906 | |
| Aug 20 2014 | ARRY | ARRAY BIOPHARMA IN ... | SNITMAN DAVID | COO and VP, Busines ... | Option Exercise | A | 0.00 | 22,906 | 0 | 22,906 | |
| Aug 20 2014 | ARRY | ARRAY BIOPHARMA IN ... | CARRUTHERS MICHAEL | CFO | Option Exercise | A | 0.00 | 25,655 | 0 | 25,655 | |
| Aug 20 2014 | ARRY | ARRAY BIOPHARMA IN ... | Needle Michael N | CMO | Option Exercise | A | 0.00 | 32,069 | 0 | 32,069 | |
| Aug 20 2014 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Option Exercise | A | 0.00 | 155,762 | 0 | 155,762 | |
| Aug 05 2014 | ARRY | ARRAY BIOPHARMA IN ... | ARRAY BIOPHARMA INC | 10% Owner | Option Exercise | C | 0.00 | 321,451 | 0 | 0 | |
| Aug 05 2014 | ARRY | ARRAY BIOPHARMA IN ... | ARRAY BIOPHARMA INC | 10% Owner | Buy | C | 0.00 | 1,030,118 | 0 | 1,030,118 | 0 to 1 M |
| Jul 10 2014 | ARRY | ARRAY BIOPHARMA IN ... | BVF PARTNERS L P/IL | Sell | J | 4.56 | 494,092 | 2,253,060 | 7,058,997 | 7.6 M to 7.1 M (-6.54 %) | |
| Apr 03 2014 | ARRY | ARRAY BIOPHARMA IN ... | SNITMAN DAVID | COO and VP, Busines ... | Option Exercise | A | 4.63 | 125,000 | 578,750 | 125,000 | |
| Apr 03 2014 | ARRY | ARRAY BIOPHARMA IN ... | MOORE JOHN R | VP, General Counsel | Option Exercise | A | 4.63 | 125,000 | 578,750 | 125,000 | |
| Apr 03 2014 | ARRY | ARRAY BIOPHARMA IN ... | CARRUTHERS MICHAEL | CFO | Option Exercise | A | 4.63 | 140,000 | 648,200 | 140,000 |